CIKCC: Efficacy of Adjuvant Cytokine-induced Killer Cells in Colon Cancer
Study Details
Study Description
Brief Summary
It has been reported that the immune status of patients with cancer were suppressed, especially those after surgery and adjuvant chemotherapy. Thus, immunotherapy may decrease the recurrence rate after surgery. CIK cells transfusion has been reported as an effect therapy in advanced cancers. In another retrospective study, investigators found that adjuvant CIK therapy would prolong the disease-free survival (DFS) for colorectal cancer patients.
The purpose of this study is to determine wether adjuvant immunotherapy with CIK cells in patients with colon cancer after operation will prolong DFS, and overall survival (OS).
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 2 |
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: synchronous CIK group After colectomy, patients will accept chemotherapy combined with cytokine-induced killer cells (CIK) therapy synchronously for 6 months. For CapeOx regimen: 3×109 CIK cells on days 1-3; Oxaliplatin 130mg/m2 on day 7; Capecitabine 1000mg/m2 twice daily on days 7-20; Repeat every 3 weeks for 6-8 cycles. For mFolfox6 regimen: Oxaliplatin 85mg/m2 IV over 2 hours on day 1; Leucovorin 400mg/m2 IV over 2 hours on day 1; 5-FU 400mg/m2 IV bolus on day 1, then 2400mg/m2 IV continuous infusion over 46-48 hous; 3×109 CIK cells on days 9-11; Oxaliplatin 85mg/m2 IV over 2 hours on day 15; Leucovorin 400mg/m2 IV over 2 hours on day 15; 5-fluorouracil (5-FU) 400mg/m2 IV bolus on day 15, then 2400mg/m2 IV continuous infusion over 46-48 hours; Repeat every 4 weeks for 5-6 cycles. |
Biological: cytokine-induced killer cells
Other Names:
|
| Experimental: sequence CIK group After colectomy, patients will accept adjuvant chemotherapy for 6 months, that is 6-8 cycles of CapeOX regimens (the same as those in arm A), or 10-12 cycles of mFolfox6 regimens(the same as those in arm A), followed by 6-8 cycles of cytokine-induced killer cells (CIK) therapy at least 2 weeks later. |
Biological: cytokine-induced killer cells
Other Names:
|
| No Intervention: control group After colectomy, patients will accept adjuvant chemotherapy for 6 months, that is 6-8 cycles of CapeOX regimens (the same as those in arm A), or 10-12 cycles of mFolfox6 regimens （the same as those in arm A）. |
Outcome Measures
Primary Outcome Measures
- DFS (Disease free survival) [Time elapsedelapsed from the date of surgery to either the date of recurrence or the date of last follow-up information,whichever come first, assessed up to 5 years.]
Patients who were recurrence free at the end of study or lost to follow-up were censored
Secondary Outcome Measures
- OS (overall survival) [Time elapsed from the date of surgery to either the date of death or the date of last follow-up information, whichever came first, assessed up to 5 years.]
Patients who were survival at the end of study or lost to follow-up were censored
- Side effect [Up to 2 years]
Any undesirable secondary effect which occurs in addition to the desired therapeutic effect of CIK or chemotherapy, during the period from the first cycle of chemotherapy or CIK infusion to the end of study. The side effects were described according to the NCI-CTCAE (National Cancer Institute-Common Terminology Criteria for Adverse Events)
- T lymphocyte subset [Up to 6 months]
During the period of CIK infusion
- QoL (quality of life) [Up to 1 year]
During the period of chemotherapy and CIK infusion
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Colon cancer in stage III or stage II with high risk after R0 resection
-
Eastern Cooperative Oncology Group (ECOG) performance status was 0 - 1;
-
Life expectancy of at least 3 months;
-
Normal bone marrow, liver, renal, heart and lung function;
-
Age between 18-80;
-
Patients who provided written informed consent for this study
Exclusion Criteria:
-
With uncontrolled other malignant tumors;
-
With uncontrolled infection or tubercle bacillus (TB) or underlying diseases that were severe or life threatening;
-
Patients who need to treat with radiotherapy;
-
Patients who accepted other immunotherapy
-
With sever mental disease or disease with central nervous system (CNS);
-
With the history of organ transplantation, including bone marrow transplantation or stem cell transplantation;
-
Patients with auto immune diseases;
-
pregnant or lactating.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Guangdong Provincial Hospital of Chinese Medicine | Guangzhou | Guangdong | China | 510120 |
Sponsors and Collaborators
- Yanjuan Zhu
Investigators
- Principal Investigator: Haibo Zhang, MD, Guangdong Provincial Hospital of Chinese Medicine, China
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- CIKCC